The latest price target for Zimmer Biomet Holdings (NYSE:ZBH) was reported by Truist Securities on February 10, 2025. The analyst firm set a price target for $113.00 expecting ZBH to rise to within 12 months (a possible 7.79% upside). 52 analyst firms have reported ratings in the last year.

The latest analyst rating for Zimmer Biomet Holdings (NYSE:ZBH) was provided by Truist Securities, and Zimmer Biomet Holdings reiterated their hold rating.

The last upgrade for Zimmer Biomet Holdings Inc happened on December 17, 2024 when JP Morgan raised their price target to $128. JP Morgan previously had a neutral for Zimmer Biomet Holdings Inc.

The last downgrade for Zimmer Biomet Holdings Inc happened on July 1, 2024 when Piper Sandler changed their price target from $140 to $115 for Zimmer Biomet Holdings Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zimmer Biomet Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zimmer Biomet Holdings was filed on February 10, 2025 so you should expect the next rating to be made available sometime around February 10, 2026.

While ratings are subjective and will change, the latest Zimmer Biomet Holdings (ZBH) rating was a reiterated with a price target of $118.00 to $113.00. The current price Zimmer Biomet Holdings (ZBH) is trading at is $104.83, which is out of the analyst’s predicted range.